Showing 8271-8280 of 8705 results for "".
- Merck's Pembrolizumab Demonstrates Positive Results in Phase III Study for Advanced Melanomahttps://practicaldermatology.com/news/mercks-pembrolizumab-demonstrates-positive-results-in-phase-iii-study-for-advanced-melanoma/2458959/Merck announced results from the randomized, pivotal Phase III study, KEYNOTE-006, in the treatment of unresectable advanced melanoma. In the study, pembrolizumab was statistically superior to ipilimumab for progression-free survival (PFS), overall survival (OS), and overall response rate (ORR).
- Provectus Opens Phase 3 Trial Enrollment for Investigational Melanoma Agenthttps://practicaldermatology.com/news/provectus-opens-phase-3-trial-enrollment-for-investigational-melanoma-agent/2458965/Provectus Biopharmaceuticals, Inc. has opened enrollment of patients for its phase 3 international FDA comparative clinical trial of PV-10 for melanoma. The study is an international multicenter, open-label, randomized controlled trial of single-agent intralesional PV-10 versus systemic chemother
- Senate Passes Bill to Repeal SGRhttps://practicaldermatology.com/news/senate-passes-bill-to-repeal-sgr/2458967/This week saw the end of the sustainable growth rate (SGR), with the US Senate passing the Medicare Access and CHIP Reauthorization Act (H.R.2) in a 92-8 vote and President Obama signing it into law. The bill, which the Hous
- Alma Lasers Releases Soprano ICE Multi-Platform Hair Removal System with Alex™ Technologyhttps://practicaldermatology.com/news/alma-lasers-releases-soprano-ice-multi-platform-hair-removal-system-with-alex-technology/2458984/Alma Lasers added the Soprano ICE ™ platform to its product portfolio. The Soprano ICE Multi-Platform combines the high absorption benefits of the Alexandrite (755nm) wavelength with the advantages of a diode laser providing more comfort for the patient during hair removal and lower mainten
- Syneron Candela Launches "Changing Lives" Program At AADhttps://practicaldermatology.com/news/syneron-candela-launches-changing-lives-program-at-aad/2458985/Syneron Medical Ltd. is introducing the Changing Lives Program, a corporate wide initiative that the company says leverages its life-changing technologies with life-changing causes. Launching at the annual American Academy of Dermatology (AAD) meeting in San Francisco on March 21, Changing Lives&
- Alma Lasers Introduces Harmony XL Pro Multi-Application Platformhttps://practicaldermatology.com/news/alma-lasers-introduces-harmony-xl-pro-multi-application-platform/2458987/Alma Lasers introduced the Harmony XL Pro™ platform to its product portfolio. The platform will be presented at the American Academy of Dermatology Meeting in San Francisco, CA from March 21 - 23 at Booth 2428. The Harmony XL Pro platform consists of multiple modules offering powerf
- Practical Dermatology® and DermTube to Offer Daily Video Coverage of AAD Annual Meetinghttps://practicaldermatology.com/news/practical-dermatology-and-dermtube-to-offer-daily-video-coverage-of-aad-annual-meeting/2458988/As the annual meeting of the American Academy of Dermatology gets underway this week, Practical Dermatology® and DermTube.com are set to bring you daily video coverage and live updates
- Aclaris Therapeutics' A-101 Achieves Positive Results in Clinical Trial for Seborrheic Keratosishttps://practicaldermatology.com/news/aclaris-therapeutics-a-101-achieves-positive-results-in-clinical-trial-for-seborrheic-keratosis/2458989/Aclaris Therapeutics, Inc.’s lead drug candidate A-10 demonstrated clinically and statistically significant improvements in removing seborrheic keratosis (SK) lesions on the face in its third Phase II clinical trial. The double-blind, vehicle-controlled Phase 2 clinical trial was designed t
- Investigational Atopic Dermatitis Cream Disappoints in Phase II Trialhttps://practicaldermatology.com/news/investigational-atopic-dermatitis-cream-disappoints-in-phase-ii-trial/2459003/Results from a phase II trial do not bode well for the future of the investigational atopic dermatitis cream MRX-6. The double-blind, parallel-group, vehicle-controlled study evaluated the safety and efficacy of MRX-6 cream 2% among 73 children suffering from mild-to-moderate atopic dermatitis. P
- Actavis Divests Rights to Doryx to Mayne Pharmahttps://practicaldermatology.com/news/actavis-divests-rights-to-doryx-to-mayne-pharma/2459007/Actavis will divest the US rights to its oral acne treatment brand Doryx and other assets related to the acne brand to Mayne Pharma, in a deal worth $50 million. Actavis currently holds the license for the distribution of Doryx in the US under a partnership between Warner Chilcott Plc, which was